Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reliant Technologies

This article was originally published in The Gray Sheet

Executive Summary

Mountain View, Calif., aesthetics device maker announces 510(k) clearance July 2 of its Fraxel re:pair laser with Fractional Deep Dermal Ablation for ablation, coagulation and skin resurfacing based on data from an ongoing, 200-patient, 10-site clinical trial. In the first phase of the trial, over 75% of patients treated with Fraxel re:pair showed improved appearance of rhytids, vascular dyschromia, pigmentation and skin laxity. Two later phases are evaluating the device for scar treatment. Reliant's other lasers on the market include Fraxel re:store for skin resurfacing and scar and wrinkle treatment, and Fraxel re:fine for gentle skin rejuvenation...

You may also be interested in...

Reliant Technologies IPO Will Support 2008 Launch Of Skin Repair Laser

Aesthetic laser manufacturer Reliant Technologies will launch its Fraxel Re:pair system for treatment of severe skin conditions in the first quarter of 2008, supported by the proceeds of a proposed initial public stock offering of up to $95 million

The Race Is On To Launch COVID-19 Antibody Home-Test In The UK

Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.

Russia May Cap Drug Prices In Fight Against COVID-19

As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts